See more : Newlox Gold Ventures Corp. (NWLXF) Income Statement Analysis – Financial Results
Complete financial analysis of Cytek Biosciences, Inc. (CTKB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cytek Biosciences, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- UniVision Engineering Limited (UVEL.L) Income Statement Analysis – Financial Results
- Ruchira Papers Limited (RUCHIRA.BO) Income Statement Analysis – Financial Results
- Xinjiang International Industry Co.,Ltd (000159.SZ) Income Statement Analysis – Financial Results
- Paslin Digital Technology Co., Ltd. (600215.SS) Income Statement Analysis – Financial Results
- Kinpo Electronics, Inc. (2312.TW) Income Statement Analysis – Financial Results
Cytek Biosciences, Inc. (CTKB)
About Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full spectrum profiling technology to further broaden potential applications across cell analysis. The company also provides reagents and kits, including cFluor reagents, which are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, which are automated plate loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific region; and through distributors or sales agents in European, Latin American, the Middle Eastern, and the Asia-Pacific countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 193.02M | 164.04M | 127.95M | 92.84M | 57.88M |
Cost of Revenue | 83.59M | 63.06M | 48.81M | 41.13M | 29.21M |
Gross Profit | 109.43M | 100.97M | 79.14M | 51.71M | 28.67M |
Gross Profit Ratio | 56.69% | 61.56% | 61.86% | 55.70% | 49.54% |
Research & Development | 44.15M | 34.86M | 24.44M | 13.69M | 8.93M |
General & Administrative | 43.97M | 34.69M | 20.83M | 9.37M | 6.74M |
Selling & Marketing | 49.15M | 33.23M | 24.71M | 14.99M | 10.24M |
SG&A | 91.62M | 67.92M | 45.54M | 24.36M | 16.98M |
Other Expenses | 0.00 | 1.02M | -1.53M | 994.00K | 252.00K |
Operating Expenses | 137.27M | 102.78M | 69.98M | 38.05M | 25.91M |
Cost & Expenses | 220.86M | 165.84M | 118.78M | 79.18M | 55.12M |
Interest Income | 6.41M | 4.62M | 49.00K | 110.00K | 711.00K |
Interest Expense | 2.07M | 2.57M | 1.74M | 333.00K | 1.00K |
Depreciation & Amortization | 9.23M | 5.70M | 1.24M | 603.00K | 309.00K |
EBITDA | -4.41M | 9.54M | 10.40M | 15.37M | -15.98M |
EBITDA Ratio | -2.28% | 2.34% | 6.01% | 16.55% | 6.97% |
Operating Income | -27.85M | -1.83M | 6.45M | 13.66M | 3.73M |
Operating Income Ratio | -14.43% | -1.11% | 5.04% | 14.71% | 6.44% |
Total Other Income/Expenses | 12.14M | 3.06M | -3.22M | 771.00K | 962.00K |
Income Before Tax | -15.71M | 1.26M | 5.95M | 14.43M | -16.29M |
Income Before Tax Ratio | -8.14% | 0.77% | 4.65% | 15.54% | -28.15% |
Income Tax Expense | -3.56M | -1.22M | 1.51M | -4.98M | 533.00K |
Net Income | -12.15M | 2.58M | 4.42M | 19.41M | -16.83M |
Net Income Ratio | -6.29% | 1.57% | 3.45% | 20.91% | -29.07% |
EPS | -0.09 | 0.02 | 0.03 | 0.02 | -0.13 |
EPS Diluted | -0.09 | 0.02 | 0.03 | 0.02 | -0.13 |
Weighted Avg Shares Out | 135.28M | 134.51M | 133.75M | 132.99M | 132.99M |
Weighted Avg Shares Out (Dil) | 135.28M | 138.56M | 133.75M | 132.99M | 132.99M |
Cytek Biosciences, Inc. (CTKB) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Cytek Biosciences, Inc.'s (CTKB) CEO Wenbin Jiang on Q3 2021 Results - Earnings Call Transcript
Cytek® Biosciences Introduces New 25-Color Immunoprofiling Assay
Cytek Biosciences to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Cytek Biosciences Reports Second Quarter 2021 Financial Results
Cytek Biosciences Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Cytek Biosciences Announces Closing of Its Initial Public Offering
Cytek Biosciences Proposes Terms For $248 Million IPO
Source: https://incomestatements.info
Category: Stock Reports